Literature DB >> 14769905

Cell-mediated immune responses in healthy children with a history of subclinical infection with Japanese encephalitis virus: analysis of CD4+ and CD8+ T cell target specificities by intracellular delivery of viral proteins using the human immunodeficiency virus Tat protein transduction domain.

Priti Kumar1, Venkatramana D Krishna2,1, Paramadevanapalli Sulochana3, Gejjehalli Nirmala3, Maganti Haridattatreya3, Vijaya Satchidanandam1.   

Abstract

Japanese encephalitis virus (JEV), a single-stranded positive-sense RNA virus of the family Flaviviridae, is the major cause of paediatric encephalitis in Asia. The high incidence of subclinical infections in Japanese encephalitis-endemic areas and subsequent evasion of encephalitis points to the development of immune responses against JEV. Humoral responses play a central role in protection against JEV; however, cell-mediated immune responses contributing to this end are not fully understood. The structural envelope (E) protein, the major inducer of neutralizing antibodies, is a poor target for T cells in natural JEV infections. The extent to which JEV non-structural proteins are targeted by T cells in subclinically infected healthy children would help to elucidate the role of cell-mediated immunity in protection against JEV as well as other flaviviral infections. The property of the Tat peptide of Human immunodeficiency virus to transduce proteins across cell membranes, facilitating intracellular protein delivery following exogenous addition to cultured cells, prompted us to express the four largest proteins of JEV, comprising 71 % of the JEV genome coding sequence, as Tat fusions for enumerating the frequencies of virus-specific CD4(+) and CD8(+) T cells in JEV-immune donors. At least two epitopes recognized by distinct HLA alleles were found on each of the non-structural proteins, with dominant antiviral Th1 T cell responses to the NS3 protein in nearly 96 % of the cohort. The data presented here show that non-structural proteins are frequently targeted by T cells in natural JEV infections and may be efficacious supplements for the predominantly antibody-eliciting E-based JEV vaccines.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14769905     DOI: 10.1099/vir.0.19531-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  5 in total

Review 1.  Japanese Encephalitis Vaccines.

Authors:  Vijaya Satchidanandam
Journal:  Curr Treat Options Infect Dis       Date:  2020-11-12

2.  Virus-specific cytolytic antibodies to nonstructural protein 1 of Japanese encephalitis virus effect reduction of virus output from infected cells.

Authors:  Venkatramana D Krishna; Manjuladevi Rangappa; Vijaya Satchidanandam
Journal:  J Virol       Date:  2009-03-04       Impact factor: 5.103

Review 3.  Preventive strategies for frequent outbreaks of Japanese encephalitis in Northern India.

Authors:  Vandana Saxena; Tapan N Dhole
Journal:  J Biosci       Date:  2008-11       Impact factor: 1.826

4.  Japanese Encephalitis Virus Persistence in Porcine Tonsils Is Associated With a Weak Induction of the Innate Immune Response, an Absence of IFNγ mRNA Expression, and a Decreased Frequency of CD4+CD8+ Double-Positive T Cells.

Authors:  Valerie Redant; Herman W Favoreel; Kai Dallmeier; Willem Van Campe; Nick De Regge
Journal:  Front Cell Infect Microbiol       Date:  2022-02-24       Impact factor: 5.293

5.  Human T cell responses to Japanese encephalitis virus in health and disease.

Authors:  Lance Turtle; Tanushka Bali; Gemma Buxton; Savita Chib; Sajesh Chan; Mohammed Soni; Mohammed Hussain; Heather Isenman; Prachi Fadnis; Manjunatha M Venkataswamy; Vishali Satishkumar; Penny Lewthwaite; Ayako Kurioka; Srinivasa Krishna; M Veera Shankar; Riyaz Ahmed; Ashia Begum; Vasanthapuram Ravi; Anita Desai; Sutee Yoksan; Stefan Fernandez; Christian B Willberg; Henrik N Kloverpris; Christopher Conlon; Paul Klenerman; Vijaya Satchidanandam; Tom Solomon
Journal:  J Exp Med       Date:  2016-05-30       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.